此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

精准微生物干预减少衰老相关性状试验 (PreMIS)

2026年10月27日 更新者:David Welsh、Louisiana State University Health Sciences Center in New Orleans

HIV感染者饮酒的老年保护精准医学策略

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

研究概览

详细说明

This is a randomized, double-blind, controlled, crossover mechanistic clinical trial in people with HIV who have recent alcohol use. Participants are randomized to receive either Limosilactobacillus reuteri probiotic or blueberry extract first for 4 weeks, followed by a 6-week washout period, then crossover to the alternate intervention for 4 weeks. Each participant receives both interventions.

Both interventions are generally recognized as safe (GRAS) dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This study is not conducted under an Investigational New Drug (IND) application and does not involve FDA-regulated investigational products.

Biospecimen collection and clinical assessments are performed at baseline and Week 4 of each intervention period. The primary analysis compares within-participant changes in immune senescence markers between interventions using a crossover design framework and accounts for period and sequence effects.

Participants will be recruited from HIV clinical care programs, affiliated clinics, and community outreach efforts in the New Orleans area.

A 6-week washout period is included to minimize potential carryover effects.

研究类型

介入性

注册 (估计的)

160

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:David A Welsh, MD
  • 电话号码:5045684634 United States
  • 邮箱:dwelsh@lsuhsc.edu

学习地点

    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • 招聘中
        • LSU Health
        • 接触:
          • David A Welsh, MD
          • 电话号码:5045684634 United States
          • 邮箱:dwelsh@lsuhsc.edu

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥40 years
  • People with HIV
  • Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)

Exclusion Criteria:

  • Probiotic use in past 3 months
  • Recent antibiotics or immunosuppressives
  • Allergy to study products
  • Pregnancy or breastfeeding
  • Inability to comply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Sequence A: Probiotic then Blueberry Extract

Participants receive probiotic for 4 weeks, washout 6 weeks, then blueberry extract for 4 weeks.

Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product.

Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product.

实验性的:Sequence B: Blueberry Extract then Probiotic

Participants receive blueberry extract for 4 weeks, washout 6 weeks, then probiotic for 4 weeks.

Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product.

Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in circulating senescent T cell numbers
大体时间:Time 0 to Week 4 of treatment period

Change in circulating CD3+CD8+CD28-CD38+ T cell count (cells/µL) during treatment period. Measured by multiparameter flow cytometry. The primary endpoint is the within-participant difference in change from baseline.

Time 0 to Week 4 of treatment period

次要结果测量

结果测量
措施说明
大体时间
Change in additional senescent T cell phenotypes
大体时间:Baseline and Week 4

Flow cytometry-defined subsets

Baseline and Week 4
Change in epigenetic age estimation
大体时间:Baseline and Week 4

Change in DNA methylation-based age estimates using epigenetic clock analyses.

Baseline and Week 4

其他结果措施

结果测量
措施说明
大体时间
Change in additional senescent T cell phenotypes
大体时间:time 0 to 4 weeks

Exploratory analyses of additional T cell phenotypes including assess additional senescence markers including lysosomal-β-galactosidase (GLB1), proinflammatory SASP (IL-1β, IL-2, IL17A, IL-18, TNFa, IFNg, HMBG1), proliferation (Ki67), CD27, CD57, and DNA damage (p-H2A.X) in T cells at multiple stages of maturation including naïve, effector, memory, and TEMRA.

time 0 to 4 weeks
Microbiome and metabolite profiles
大体时间:Baseline and Week 4

Stool microbiome (phylogenetic analysis and bacterial genes quantification) and metabolite analyses.

Baseline and Week 4

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:David A Welsh, MD、LSU Health New Orleans

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月1日

初级完成 (估计的)

2029年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2026年2月22日

首先提交符合 QC 标准的

2026年3月5日

首次发布 (实际的)

2026年3月10日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月27日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data will be shared upon reasonable request following publication, subject to data use agreements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅